Julia V. Roumiantseva

1, Ostrovitianova Str
Moscow, MOW 117997, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Prognostic impact and clinical value of low levels of flow cytometric MRD at the end of induction in childhood B-lineage acute lymphoblastic leukemia: Results of study ALL-MB 2015.

Prognostic impact and clinical value of low levels of flow cytometric MRD at the end of induction in childhood B-lineage acute lymphoblastic leukemia: Results of study ALL-MB 2015.

Journal: HemaSphere

Published: January 20, 2025

Analysis of Antigen Expression in T-Cell Acute Lymphoblastic Leukemia by Multicolor Flow Cytometry: Implications for the Detection of Measurable Residual Disease.

Analysis of Antigen Expression in T-Cell Acute Lymphoblastic Leukemia by Multicolor Flow Cytometry: Implications for the Detection of Measurable Residual Disease.

Journal: International journal of molecular sciences

Published: January 09, 2025

Genetic Diversity in KMT2A -r and KMT2A -Wt Groups: Assessing the Prognostic Value of Markers in BCP-ALL Among Infants.

Genetic Diversity in KMT2A -r and KMT2A -Wt Groups: Assessing the Prognostic Value of Markers in BCP-ALL Among Infants.

Journal: International journal of laboratory hematology

Published: November 22, 2024

TP53 variants underlying pediatric low-hypodiploidy B-cell acute lymphoblastic leukemia demonstrate diverse origins and may persist as a hematopoietic clone in remission.

TP53 variants underlying pediatric low-hypodiploidy B-cell acute lymphoblastic leukemia demonstrate diverse origins and may persist as a hematopoietic clone in remission.

Journal: EJHaem

Published: May 30, 2024

Blinatumomab as postremission therapy replaces consolidation and substantial parts of maintenance chemotherapy and results in stable MRD negativity in children with newly diagnosed B-lineage ALL.

Blinatumomab as postremission therapy replaces consolidation and substantial parts of maintenance chemotherapy and results in stable MRD negativity in children with newly diagnosed B-lineage ALL.

Journal: Journal for immunotherapy of cancer

Published: May 07, 2024

Immunophenotypic but Not Genetic Changes Reclassify the Majority of Relapsed/Refractory Pediatric Cases of Early T-Cell Precursor Acute Lymphoblastic Leukemia.

Immunophenotypic but Not Genetic Changes Reclassify the Majority of Relapsed/Refractory Pediatric Cases of Early T-Cell Precursor Acute Lymphoblastic Leukemia.

Journal: International journal of molecular sciences

Published: March 20, 2024

Flow cytometric minimal residual disease measurement accounting for cytogenetics in children with non-high-risk acute lymphoblastic leukemia treated according to the ALL-MB 2008 protocol.

Flow cytometric minimal residual disease measurement accounting for cytogenetics in children with non-high-risk acute lymphoblastic leukemia treated according to the ALL-MB 2008 protocol.

Journal: Cancer medicine

Published: November 17, 2023

A Single Dose of PEG-Asparaginase at the Beginning of Induction Not Only Accelerates MRD Clearance but Also Improves Long-Term Outcome in Children with B-Lineage ALL.

A Single Dose of PEG-Asparaginase at the Beginning of Induction Not Only Accelerates MRD Clearance but Also Improves Long-Term Outcome in Children with B-Lineage ALL.

Journal: Cancers

Published: October 17, 2023

Laboratory characterization of the pediatric B/T subtype of mixed-phenotype acute leukemia: Report of a case series.

Laboratory characterization of the pediatric B/T subtype of mixed-phenotype acute leukemia: Report of a case series.

Journal: American journal of clinical pathology

Published: July 11, 2023

A simple procedure to identify children with B-lineage acute lymphoblastic leukemia who can be successfully treated with low or moderate intensity: Sequential versus single-point minimal residual disease measurement.

A simple procedure to identify children with B-lineage acute lymphoblastic leukemia who can be successfully treated with low or moderate intensity: Sequential versus single-point minimal residual disease measurement.

Journal: Pediatric blood & cancer

Published: November 10, 2022

Flow cytometric MRD at the end of consolidation in childhood B-lineage acute lymphoblastic leukemia has significant prognostic value but limited clinical implications: Results of study ALL-MB 2008.

Flow cytometric MRD at the end of consolidation in childhood B-lineage acute lymphoblastic leukemia has significant prognostic value but limited clinical implications: Results of study ALL-MB 2008.

Journal: Leukemia research

Published: October 08, 2022

One-point flow cytometric MRD measurement to identify children with excellent outcome after intermediate-risk BCP-ALL: results of the ALL-MB 2008 study.

One-point flow cytometric MRD measurement to identify children with excellent outcome after intermediate-risk BCP-ALL: results of the ALL-MB 2008 study.

Journal: Journal of cancer research and clinical oncology

Published: August 19, 2022

Showing 1-12 of 20

Last Updated: 09/26/2026